EWSR1 and Ewing sarcoma: Although work is currently underway to develop direct inhibitors of EWS-FLI1, an alternative therapeutic approach in Ewing sarcoma is to identify downstream targets of EWS-FLI1, or unique vulnerabilities incurred by the oncoprotein [11–19].